<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03518138</url>
  </required_header>
  <id_info>
    <org_study_id>Q122-2001</org_study_id>
    <nct_id>NCT03518138</nct_id>
  </id_info>
  <brief_title>Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Q-122 for the Treatment of Vasomotor Symptoms in Female Breast Cancer Patients/Survivors Taking Tamoxifen or an Aromatase Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Que Oncology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Que Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 proof-of-concept (POC) study designed to determine the effectiveness of
      Q-122 for the treatment of Vasomotor Symptoms (VMS) versus placebo. Participants who meet all
      eligibility criteria following the Screening/Run-In period will be randomized to 1 of 2
      treatment arms; blinded Q-122 or placebo for a period of 28 days. All participants will be
      followed for a 2-week, drug-free, follow-up period after their last dose of blinded
      Q-122/placebo before termination from the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vasomotor symptoms (VMS) are significant in postmenopausal women with the most effective
      medications for relief being hormonal preparations. Non-hormonal medications have
      demonstrated efficacy but at a far lower level than estrogen replacement therapy. For women
      with a history of breast cancer, hormone replacement therapy is often contraindicated and is
      not an option for women receiving endocrine therapy including tamoxifen (TAM) and aromatase
      inhibitors (AI). Breast cancer survivors, and women receiving endocrine therapy in
      particular, have a high rate of problematic hot flashes. In an open label Phase 1 study of
      the safety and activity of Q-122 in breast cancer patients taking TAM or an AI, 8 of 9 women
      who received at least 1 dose of 100 mg and 10 of 11 women who received at least 1 dose of 200
      mg had a reduction in hot flashes of 2 or more per day, the FDA criteria for anti-VMS
      activity. This study will define the effect of Q-122 versus placebo in a population of women
      with a history of or current breast cancer who have an average of 50 or more moderate to
      severe hot flashes per week.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2018</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hot Flash Severity Score (HFSS)</measure>
    <time_frame>4 weeks</time_frame>
    <description>The primary efficacy outcome measure will be the change from baseline in the HFSS for moderate and severe hot flashes (HFSS-m/s) calculated for each treatment week by multiplying the severity by the frequency using the following formula: (2 x number of moderate) + (3 x number of severe)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Vasomotor Symptoms (VMS)</condition>
  <arm_group>
    <arm_group_label>Group 1, study drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>65 patients treated with Q-122, 100 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2, placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>65 patients treated with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Q-122</intervention_name>
    <description>oral capsule of Q-122</description>
    <arm_group_label>Group 1, study drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral capsule of placebo</description>
    <arm_group_label>Group 2, placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be a female, aged between 18 - 70 years on the day of informed consent.

          2. Have a history of or current breast cancer and currently taking tamoxifen or an
             aromatase inhibitor.

          3. On a stable dose of TAM or an AI for a minimum of 30 days before the Screening Visit
             and no anticipated need to change the dose for the duration of the study.

          4. Experience an average of at least 50 moderate to severe hot flashes/week for the 2
             weeks immediately preceding the Run-In Visit (i.e., during the Screening period).

          5. If on thyroid medication, on a stable dose for a minimum of 30 days before the
             Screening Visit and no anticipated need to change the dose for the duration of the
             study.

          6. Willing and able to complete the daily participant diary, attend all study visits, and
             participate in all study procedures.

          7. Able to provide informed consent.

        Exclusion Criteria:

          1. Childbearing potential, pregnancy, or lactation except in patients who are on stable
             dose of AI in combination with luteinizing hormone releasing hormone agonists such as
             Zoladex, Leuprolide (Lupron) or equivalent. Non-childbearing potential is defined as
             physiologically incapable of becoming pregnant by one of the following:

               -  Has had a partial or complete hysterectomy or

               -  Has had a bilateral oophorectomy or

               -  Has had a bilateral tubal ligation or fallopian tube inserts or

               -  Is post-menopausal (amenorrhea &gt; 1 year) confirmed by levels of follicle
                  stimulating hormone (FSH). FSH levels may be lower in menopausal women treated
                  with tamoxifen when compared with FSH levels appropriate for confirming menopause
                  in women not treated with tamoxifen. For those patients who are on stable dose of
                  tamoxifen, confirmation of menopause is based on the clinical opinion of the PI
                  and medical monitor on a 'case-by-case basis'.

          2. Currently experiencing undiagnosed vaginal bleeding.

          3. Women with advanced breast cancer (Stage 4).

          4. Greater than 60% reduction in the frequency of moderate to severe hot flashes during
             the 1-week single blind Run-In period or inability to correctly record hot flashes
             and/or drug dosing in the participant diary.

          5. Participation in another clinical or surgical trial within 30 days prior to screening
             or during the study without the prior written consent of the Medical Monitor.

          6. Gastrointestinal, liver, kidney or other conditions which could interfere with the
             absorption, distribution, metabolism or excretion of Q-122 at PI discretion.

          7. Untreated overt hyperthyroidism.

          8. Have any other medical condition, clinically important systemic disease or significant
             co-morbidities or any finding during Screening that in the judgment of the
             investigator puts the participant at increased risk by participation in this study, or
             that may affect the reliability of participant diary entries.

          9. Known inability to complete all study visits and study assessments for scheduling or
             other reasons.

         10. BMI &gt; 40 kg/m2; Participants with a BMI greater than 40 kg/m2 may be enrolled on a
             case-by-case basis if approved by the Medical Monitor and if the participant is not
             deemed at increased risk of adverse effects based on body habitus and cardiovascular
             health.

         11. Women with a history of, or current evidence of, abuse of alcohol or any drug
             substance, or who regularly drink more than 3 standard drinks per day.

         12. Uncontrolled systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥95 mmHg on
             3 consecutive readings within the screening visit.

         13. Abnormal laboratory findings:

               1. Hemoglobin &lt; 9.5 g/dL (g/L); or any abnormal values that are deemed clinically
                  significant by the investigator should be discussed with the medical monitor
                  before being deemed ineligible.

               2. Fasting ALT, AST, GGT, or bilirubin greater than twice the upper limit of normal
                  that is confirmed on a second sample.

               3. &lt;60 eGFR mL/min/1.73 m2.

         14. In the opinion of the investigator, have substantial risk of disease progression
             within the 3 months following screening and/or who potentially may require further
             treatment for their breast cancer during the study period including follow-up.

         15. Any other reason which in the investigator's opinion makes the participant unsuitable
             for a clinical trial.

         16. On any medications, either prescription or over-the-counter that are being taken
             solely for the purpose of treating VMS including SSRI/SNRI, gabapentin or pregabalin.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>North Georgia Clinical Research</name>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Williams</last_name>
      <phone>678-494-5735</phone>
      <email>jwilliams@ngclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Bram Wieskopf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Nursing</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Conder</last_name>
      <phone>317-278-5632</phone>
      <email>iutrials@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Anna Maria Storniolo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morgan Buckley</last_name>
      <phone>410-502-5838</phone>
      <email>HopkinsBreastTrials@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Vered Stearns</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brighams and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleta Wiley</last_name>
      <phone>617-525-9627</phone>
      <email>questudy@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Hadine Joffe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Rago</last_name>
      <phone>631-638-0852</phone>
      <email>Molly.Rago2@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Lea Baer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scoot &amp; White Medical Center</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gates Anderson</last_name>
      <phone>254-724-5889</phone>
      <email>Gates.Anderson@bswhealth.org</email>
    </contact>
    <investigator>
      <last_name>Ashwini Bhat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessie Bennett</last_name>
      <phone>+61 8 8222 6759</phone>
      <email>jessie.bennett@sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Robert Whitfield</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICON Group, Icon Cancer Care Wesley</name>
      <address>
        <city>Brisbane</city>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tori Furner</last_name>
      <phone>+61 7 3737 4583</phone>
      <email>tori.furner@icon.team</email>
    </contact>
    <investigator>
      <last_name>Nicole McCarthy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>School of Public Health and Preventive Medicine, Monash University</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Reading</last_name>
      <phone>+61 3 9903 0836</phone>
      <email>michelle.reading@monash.edu</email>
    </contact>
    <investigator>
      <last_name>Susan Davis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Women's Hospital</name>
      <address>
        <city>Melbourne</city>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shona Darby</last_name>
      <phone>+61 3 8345 2217</phone>
      <email>shona.darby@thewomens.org.au</email>
    </contact>
    <investigator>
      <last_name>Martha Hickey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keogh Institute for Medical Research</name>
      <address>
        <city>Perth</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Smilja Dragovic</last_name>
      <phone>+61 8 6457 2475</phone>
      <email>smilja@kimr.org</email>
    </contact>
    <investigator>
      <last_name>Bronwyn Stuckey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Health Research Institute of Australia</name>
      <address>
        <city>Sydney</city>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinzhu Liu</last_name>
      <phone>+61 2 9382 6278</phone>
      <email>jz.liu@unsw.ed.au</email>
    </contact>
    <investigator>
      <last_name>John Eden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Sydney</city>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yue Zhao</last_name>
      <phone>+61 2 9463 1463</phone>
      <email>yue.zhao1@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Rodney Baber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Optimal Clinical Trials</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudette Lionnet</last_name>
      <phone>+64 9 303 4987</phone>
      <email>claudette@optimalclinicaltrials.com</email>
    </contact>
    <investigator>
      <last_name>Penelope Montgomery</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eibhlin Corrigan</last_name>
      <phone>+64 9 307 4949</phone>
      <email>eibhlinc@adhb.govt.nz</email>
    </contact>
    <investigator>
      <last_name>David Porter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christchurch Clinical Studies Trust Ltd</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Warner</last_name>
      <phone>+64 3 372 9477</phone>
      <email>Mark@ccst.com.nz</email>
    </contact>
    <investigator>
      <last_name>Christopher Wynne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>P3 Research - Hawkes Bay</name>
      <address>
        <city>Havelock North</city>
        <zip>4130</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Wallace</last_name>
      <phone>+64 6 824 3072</phone>
      <email>JudiW@p3research.co.nz</email>
    </contact>
    <investigator>
      <last_name>Nine Smuts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>P3 Research - Tauranga</name>
      <address>
        <city>Tauranga</city>
        <zip>3110</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dianne Ward</last_name>
      <phone>+64 7 579 0453</phone>
      <email>dianne@p3research.co.nz</email>
    </contact>
    <investigator>
      <last_name>Katrina Allen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>April 25, 2018</study_first_submitted>
  <study_first_submitted_qc>April 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2018</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

